Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Rob C. who wrote (1137)	2/10/1999 7:21:00 PM
From: Anthony Wong	Respond to of 2539

02/10 15:43 Monsanto <MTC.N> says GM cotton sales eyed for EU CHICAGO, Feb 10 (Reuters) - U.S. biotechnology developer Monsanto Co. <MTC.N> on Wednesday said it was seeking approval to commercially grow and sell genetically-modified (GM) cotton seeds in the European Union, particularly Spain and Greece. Monsanto director of bio-technology communications Gary Barton, however said the company's request submitted to the European Union through Spain in 1996 was still pending. "We presented our dossiers to Spain in 1996 to obtain regulatory approval for Monsanto to commercially grow and sell genetically-modified cotton seeds in Europe," he said. He said Monsanto has been conducting field trials with GM cotton, which is insect-resistant, in both the countries. He was responding to remarks by a Spanish Agriculture Ministry official on Wednesday that Monsanto had sought permission from the Spanish government to sell GM cotton seeds in Spain. A decision was expected in coming weeks, the official told Reuters in Lisbon. In Lisbon, an Environment Ministry spokesman said Monsanto had made no similar request to Portugal. A British newspaper reported this week that Monsanto was applying to grow GM cotton in Spain and Portugal.

To: Rob C. who wrote (1137)	2/10/1999 7:29:00 PM
From: Anthony Wong	Respond to of 2539

Feb 10, 1999 (6:27 PM ET) - The Motley Fool Evening News Life sciences company Monsanto Co. (NYSE:MTC - news) gained $2 1/4 to $47 3/8 on news that its new anti-arthritis drug Celebrex is selling rapidly, generating 83,000 prescriptions in only its third week on the market. In comparison, Warner-Lambert's (NYSE:WLA - news) popular Lipitor cholesterol-lowering drug, itself a fast seller right out of the starting blocks, logged "only" 14,000 prescriptions during its third week, according to a report by health data tracker NDC Health Information Services. While the quick pace is definitely good news for Monsanto, the behind-the-scenes winner in this pharmacological version of the 100-meter dash may very well be Pfizer (NYSE:PFE - news) . Since Pfizer is co-marketing both Celebrex and Lipitor, a fast start for both drugs translates into an equally quick expansion of the "Alliance Revenue" line of Pfizer's income statement in coming quarters. Pfizer also picked up $1 1/2 to $126 1/2 today.